Evidence map›Paper›PMID 37388711›Full record

ArticleClinical and translational radiation oncology2023

Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer.

Angel Montero, Raquel Ciérvide, Carmen Cañadillas, Beatriz Álvarez, Mariola García-Aranda, Rosa Alonso, Mercedes López, Xin Chen-Zhao, Leyre Alonso, Jeannete Valero and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07020780 (Five Fractions Ultrahypofractionated Whole Breast Radiotherapy and Simultaneous Integrated Boost to the Tumor Bed, for Breast Cancer Patients With Unfavorable Characteristics), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07020780 narecruitingnot on this mapstarted 2025, after this paper: background citation

Five Fractions Ultrahypofractionated Whole Breast Radiotherapy and Simultaneous Integrated Boost to the Tumor Bed, for Breast Cancer Patients With Unfavorable Characteristics

TypeinterventionalSponsorIRCCS San RaffaeleRan2025 to 2035Enrolled458ConditionsBreast CancerArmsAdjuvant 5 fractions whole breast irradiation with simultaneous integrated boost to the tumor bed
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Global perspective on implementing ultra-hypofractionated radiation therapy in breast cancer: a survey-based analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  6. Article
  7. Ultra-hypofractionated 5-fraction radiation therapy for early breast cancer into whole breast and regional nodes: experience in a tertiary hospital.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Observational
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Angel MonteroDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Raquel CiérvideDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Carmen CañadillasDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Beatriz ÁlvarezDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Mariola García-ArandaDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Rosa AlonsoDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Mercedes LópezDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Xin Chen-ZhaoDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Leyre AlonsoDepartment of Medical Physics, HM Hospitales, Madrid, Spain.
Jeannete ValeroDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Emilio SánchezDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Ovidio HernandoDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Paz García de AciluDepartment of Medical Physics, HM Hospitales, Madrid, Spain.
Pedro Fernandez-LetónDepartment of Medical Physics, HM Hospitales, Madrid, Spain.
Carmen RubioDepartment of Medical Physics, HM Hospitales, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Whole-breast irradiation (WBI) after breast conserving surgery (BCS) is indicated to improve loco-regional control and survival. Former studies showed that addition of tumor bed boost in all age groups significantly improved local control although no apparent impact on overall survival but with an increased risk of worse cosmetic outcome. Even though shortened regimens in 3 weeks are considered the standard, recent studies have shown the non-inferiority of a treatment regimen of 5 fractions in one-week in both locoregional control and toxicity profile, although simultaneous integrated boost (SIB) in this setting has been scarcely studied. Materials and Methods: From March-2020 to March-2022, 383 patients with early breast cancer diagnosis and a median age of 56 years-old (range 30-99)were included in a prospective registry of ultra-hypofractionated WBI up to a total dose of 26 Gy in 5.2 Gy/fraction with a SIB of 29 Gy in 5.8 Gy/fraction in 272 patients (71%), 30-31 Gy in 6-6.2 Gy/fraction in 111 patients (29%) with close/focally affected margins. Radiation treatment was delivered by conformal 3-D technique in 366 patients (95%), VMAT in 16patients (4%) and conformal 3-D with deep inspiration breath hold (DIBH) in 4patients (1%). Ninety-three per cent of patients received endocrine therapy and 43% systemic or targeted chemotherapy. Development of acute skin complications was retrospectively reviewed. Results: With a median follow-up of 18 months (range 7-31), all patients are alive without evidence of local, regional or distant relapse. Acute tolerance was acceptable, with null o mild toxicity: 182 (48%) and 15 (4%) patients developed skin toxicity grade 1 and 2 respectively; 9 (2%) and 2 (0.5%) patients breast edema grade 1and 2 respectively. No other acute toxicities were observed. We also evaluated development of early delayed complications and observed grade 1 breast edema in 6 patients (2%); grade 1 hyperpigmentation in 20 patients (5%); and grade 1 and 2 breast induration underneath boost region in 10(3%) and 2 patients (0.5%) respectively. We found a statistically significant correlation between the median PTV Conclusion: Ultra-hypofractionated WBI + SIB in 5 fractions over one-week is feasible and well tolerated, although longer follow-up is necessary to confirm these results.

Indexed as

Early breast cancerSimultaneous boostUltra-hypofractionated radiation treatment

Identifiers

PMID37388711
PMCPMC10300060

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.